How do you approach systemic therapy for metastatic prostate cancer in geriatric patient when progressed to mCRPC on ADT alone?

This is an important question and requires a careful balancing of scientific and medical knowledge versus clinical skill.

(1) The first key issue is the context of the question -- what is meant by "frail", what has caused the "frailty", and what is the anticipated life expectancy of the patient. If ...

I agree with Dr. Raghavan completely that the term 'geriatric' in oncology should not refer to actual age, but rather to physiologic measures of frailty and health, in order to avoid discrimination and withholding of life prolonging therapies unnecessarily based simply on age. The average age of dia...